INCY Incyte Corp.
$123.89
Incyte Corp. (INCY) is expected to report earnings on November 2, 2026, before the market open. The consensus earnings estimate is a loss of $3.58 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +4.1% since its last earnings release on July 28, 2026.
Incyte Beat Expectations, Raises Guidance to be Closer to Estimates
Tuesday, July 28, 2026 · 7:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 2
Monday · 7:00 AM ET
Earnings Whisper
-
vs ($3.58)
(GAAP)
Rev est $1.48B
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP
$124.53
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Incyte Corp.
Incyte Corp is a biopharmaceutical company. It discovers, develops and commercializes proprietary small molecule drugs to treat serious unmet medical needs, mainly in oncology.
Sector
Healthcare
Industry
Biotechnology
Held By 14 ETFs, by dollar flow
- XT iShares Exponential Technologies ETF
- XT iShares Exponential Technologies ETF
- IYH iShares U.S. Healthcare ETF
- IYH iShares U.S. Healthcare ETF
- XLV Health Care Select Sector SPDR Fund
- XLV Health Care Select Sector SPDR Fund
- IXJ iShares Global Healthcare ETF
- IXJ iShares Global Healthcare ETF
- QQQJ Invesco NASDAQ Next Gen 100 ETF
- QQQJ Invesco NASDAQ Next Gen 100 ETF
- BBH VanEck Biotech ETF
- BBH VanEck Biotech ETF
- IDNA iShares Genomics Immunology and Healthcare ETF
- IDNA iShares Genomics Immunology and Healthcare ETF
Charts powered in part by Lightweight Charts™ by TradingView.